Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synergistic sedation of sufentanil combined with ciprofol
ChiCTR2500108592Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ciprofol and sufentanil (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Duration of loss of consciousness and BIS <= 60 following ciprofol injection. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ciprofolsufentanil
Beyond the preview
Go deeper on ChiCTR2500108592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108592.